It’s a familiar story: a biotechnology company develops a promising product but falls short of sales projections. The company then cuts staff, realigns resources, and turns to startups to fill its depleted pipeline.
While this scenario does play out in pharmaceuticals, it also describes what is happening in agriculture. Big ag companies face pressures to develop agricultural innovations and deliver financial returns. Agbio startups vie to fill big ag product pipelines. But even though motives driving agbio deals are similar to those in pharma, agbio startups can face steeper challenges.
{iframe}http://www.xconomy.com/raleigh-durham/2016/03/07/biotech-dealmaking-is-tough-but-agbio-deals-prove-even-tougher/?utm_source=Xconomy&utm_campaign=e87ab2e6d7-NEWSLETTER_all_stories&utm_medium=email&utm_term=0_2aa91c0bc9-e87ab2e6d7-288460969{/iframe}